Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing

Oral presentation on novel allosteric ELXR epigenetic silencer showcases Scribe’s development in achieving highly precise, potent, and durable target repression XE gene editor oral presentation demonstrates how mechanistic insight underlying guide potency and AI-based predictive modeling supports